Mereo Biopharma Group Plc ADR (NASDAQ:MREO) shares, rose in value on Friday, May 30, with the stock price down by -2.71% to the previous day’s close as strong demand from buyers drove the stock to $2.15.
Actively observing the price movement in the last trading, the stock closed the session at $2.21. Referring to stock’s 52-week performance, its high was $5.02, and the low was $1.58. On the whole, MREO has fluctuated by -16.99% over the past month.
With the market capitalization of Mereo Biopharma Group Plc ADR currently standing at about $341.85 million, investors are eagerly awaiting this quarter’s results, scheduled for in June.
The stock’s technical analysis shows that the price of MREO currently trading nearly -7.33% and -6.20% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 40.94, while the 7-day volatility ratio is showing 1.98% which for the 30-day chart, stands at 3.59%. Furthermore, Mereo Biopharma Group Plc ADR (MREO)’s beta value is 0.42, and its average true range (ATR) is 0.15.
A comparison of Mereo Biopharma Group Plc ADR (MREO) with its peers suggests the former has fared considerably weaker in the market. MREO showed an intraday change of -2.71% in last session, and over the past year, it shrunk by -35.82%%.
Data on historical trading for Mereo Biopharma Group Plc ADR (NASDAQ:MREO) indicates that the trading volumes over the past 3 months, they’ve averaged 1.39 million. According to company’s latest data on outstanding shares, there are 159.00 million shares outstanding.
Nearly 9.53% of Mereo Biopharma Group Plc ADR’s shares belong to company insiders and institutional investors own 60.80% of the company’s shares. The stock has fallen by -38.57% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the MREO stock heading into the next quarter.
